Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros


Bases de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Eur J Pharm Sci ; 114: 346-355, 2018 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-29305070

RESUMO

The objective of this study was to explore the feasibility of using alginate as a promising diphase solid dispersion carrier to enhance dissolution rate of BCS II drugs with improved stability. Taking lovastatin and indomethacin as model drugs, solvent evaporation method was used to prepare solid dispersions. The drug/polymer compatibility was predicted by Hansen solubility parameter and the drug/polymer ratio was screened based on dissolution study, drug existing state in solid dispersion was characterized by DSC and XRPD. Accelerated stability of the solid dispersion was assessed and compared with that of HPMCAS based system. Phase behavior of the solid dispersion before and after stability study was characterized using polar microscope and Raman mapping. It was found that the optimal drug/alginate ratio was drug dependent and drug existing state was related to drug/alginate miscibility. Stability studies revealed that alginate improved the stability of solid dispersions regardless of drug existing state and a better stability was obtained compared to HPMCAS based system. Raman mapping and SEM study revealed that micro phase separation of solid dispersion was the main reason for the slight decrease in drug dissolution after accelerating experiment. In conclusion, alginate can be used as a promising diphase solid dispersion carrier with significantly improved dissolution rate and storage stability.


Assuntos
Alginatos/química , Alginatos/metabolismo , Portadores de Fármacos/química , Portadores de Fármacos/metabolismo , Liberação Controlada de Fármacos , Alginatos/administração & dosagem , Portadores de Fármacos/administração & dosagem , Estabilidade de Medicamentos , Armazenamento de Medicamentos , Ácido Glucurônico/administração & dosagem , Ácido Glucurônico/química , Ácido Glucurônico/metabolismo , Ácidos Hexurônicos/administração & dosagem , Ácidos Hexurônicos/química , Ácidos Hexurônicos/metabolismo , Indometacina/administração & dosagem , Indometacina/metabolismo , Lovastatina/administração & dosagem , Lovastatina/metabolismo , Solubilidade
2.
Colloids Surf B Biointerfaces ; 140: 421-429, 2016 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-26784658

RESUMO

Bacterial cellulose (BC) films modified by the in situ method with the addition of alginate (Alg) during the microbial cultivation of Gluconacetobacter hansenii under static conditions increased the loading of doxorubicin by at least three times. Biophysical analysis of BC-Alg films by scanning electron microscopy, thermogravimetry, X-ray diffraction and FTIR showed a highly homogeneous interpenetrated network scaffold without changes in the BC crystalline structure but with an increased amorphous phase. The main molecular interactions determined by FTIR between both biopolymers clearly suggest high compatibility. These results indicate that alginate plays a key role in the biophysical properties of the hybrid BC matrix. BC-Alg scaffold analysis by nitrogen adsorption isotherms revealed by the Brunauer-Emmett-Teller (BET) method an increase in surface area of about 84% and in pore volume of more than 200%. The Barrett-Joyner-Halenda (BJH) model also showed an increase of about 25% in the pore size compared to the BC film. Loading BC-Alg scaffolds with different amounts of doxorubicin decreased the cell viability of HT-29 human colorectal adenocarcinoma cell line compared to the free Dox from around 95-53% after 24h and from 63% to 37% after 48 h. Dox kinetic release from the BC-Alg nanocomposite displayed hyperbolic curves related to the different amounts of drug payload and was stable for at least 14 days. The results of the BC-Alg nanocomposites show a promissory potential for anticancer therapies of solid tumors.


Assuntos
Alginatos/química , Celulose/química , Doxorrubicina/farmacologia , Gluconacetobacter/química , Antibióticos Antineoplásicos/química , Antibióticos Antineoplásicos/farmacocinética , Antibióticos Antineoplásicos/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Celulose/metabolismo , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/patologia , Doxorrubicina/química , Doxorrubicina/farmacocinética , Liberação Controlada de Fármacos , Ácido Glucurônico/química , Células HT29 , Ácidos Hexurônicos/química , Humanos , Microscopia Eletrônica de Varredura , Nanocompostos/química , Nanocompostos/ultraestrutura , Espectroscopia de Infravermelho com Transformada de Fourier , Termogravimetria , Alicerces Teciduais/química , Difração de Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA